25 XP   0   0   10

Samsung Biologics Co Ltd
Buy, Hold or Sell?

Let's analyse Samsung Biologics Co Ltd together

PenkeI guess you are interested in Samsung Biologics Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Samsung Biologics Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Samsung Biologics Co Ltd

I send you an email if I find something interesting about Samsung Biologics Co Ltd.

Quick analysis of Samsung Biologics Co Ltd (30 sec.)










What can you expect buying and holding a share of Samsung Biologics Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩138,119.15
Expected worth in 1 year
₩150,005.77
How sure are you?
73.1%

+ What do you gain per year?

Total Gains per Share
₩11,886.62
Return On Investment
1.5%

For what price can you sell your share?

Current Price per Share
₩780,000.00
Expected price per share
₩743,000 - ₩878,000
How sure are you?
50%

1. Valuation of Samsung Biologics Co Ltd (5 min.)




Live pricePrice per Share (EOD)

₩780,000.00

Intrinsic Value Per Share

₩292,938.03 - ₩351,857.95

Total Value Per Share

₩431,057.18 - ₩489,977.10

2. Growth of Samsung Biologics Co Ltd (5 min.)




Is Samsung Biologics Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$6.8b$5.3b$1.2b19.6%

How much money is Samsung Biologics Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$150m$139.6m$10.4m7.0%
Net Profit Margin22.8%26.3%--

How much money comes from the company's main activities?

3. Financial Health of Samsung Biologics Co Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#10 / 1010

Most Revenue
#26 / 1010

Most Profit
#23 / 1010

Most Efficient
#71 / 1010

What can you expect buying and holding a share of Samsung Biologics Co Ltd? (5 min.)

Welcome investor! Samsung Biologics Co Ltd's management wants to use your money to grow the business. In return you get a share of Samsung Biologics Co Ltd.

What can you expect buying and holding a share of Samsung Biologics Co Ltd?

First you should know what it really means to hold a share of Samsung Biologics Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Samsung Biologics Co Ltd is ₩780,000. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Samsung Biologics Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Samsung Biologics Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩138,119.15. Based on the TTM, the Book Value Change Per Share is ₩2,971.65 per quarter. Based on the YOY, the Book Value Change Per Share is ₩14,026.79 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Samsung Biologics Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps2.860.0%2.110.0%1.960.0%1.230.0%1.010.0%
Usd Book Value Change Per Share2.800.0%2.080.0%9.820.0%2.790.0%3.720.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share2.800.0%2.080.0%9.820.0%2.790.0%3.720.0%
Usd Price Per Share532.00-520.28-567.88-480.80-438.04-
Price to Earnings Ratio46.52-66.86-85.82-86.58-2.90-
Price-to-Total Gains Ratio190.15-269.60-130.32-303.74-14.48-
Price to Book Ratio5.50-5.60-8.36-8.63-8.39-
Price-to-Total Gains Ratio190.15-269.60-130.32-303.74-14.48-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share546
Number of shares1
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share2.082.79
Usd Total Gains Per Share2.082.79
Gains per Quarter (1 shares)2.082.79
Gains per Year (1 shares)8.3211.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
108-20111
2017602212
30251403323
40332204534
50423005645
60503806756
70584607867
80675408978
907562010089
10083700112100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%18.02.00.090.0%20.06.00.076.9%20.06.00.076.9%
Book Value Change Per Share4.00.00.0100.0%11.01.00.091.7%17.03.00.085.0%19.06.01.073.1%19.06.01.073.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.026.00.0%0.00.026.00.0%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%17.03.00.085.0%19.06.01.073.1%19.06.01.073.1%

Fundamentals of Samsung Biologics Co Ltd

About Samsung Biologics Co Ltd

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, Contract Development and Manufacturing Organization Business, and Biopharmaceutical Development and Commercialization Business. It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Fundamental data was last updated by Penke on 2024-04-16 04:49:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is overpriced.

1.1. Profitability of Samsung Biologics Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Samsung Biologics Co Ltd earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Samsung Biologics Co Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 27.1% means that ₩0.27 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Samsung Biologics Co Ltd:

  • The MRQ is 27.1%. The company is making a huge profit. +2
  • The TTM is 22.8%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ27.1%TTM22.8%+4.2%
TTM22.8%YOY26.3%-3.5%
TTM22.8%5Y21.0%+1.8%
5Y21.0%10Y21.0%+0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ27.1%-207.2%+234.3%
TTM22.8%-216.8%+239.6%
YOY26.3%-282.3%+308.6%
5Y21.0%-436.8%+457.8%
10Y21.0%-597.3%+618.3%
1.1.2. Return on Assets

Shows how efficient Samsung Biologics Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Samsung Biologics Co Ltd to the Biotechnology industry mean.
  • 1.8% Return on Assets means that Samsung Biologics Co Ltd generated ₩0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Samsung Biologics Co Ltd:

  • The MRQ is 1.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM1.3%+0.5%
TTM1.3%YOY1.5%-0.1%
TTM1.3%5Y1.2%+0.1%
5Y1.2%10Y1.1%+0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8%-13.3%+15.1%
TTM1.3%-12.8%+14.1%
YOY1.5%-11.6%+13.1%
5Y1.2%-13.8%+15.0%
10Y1.1%-15.6%+16.7%
1.1.3. Return on Equity

Shows how efficient Samsung Biologics Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Samsung Biologics Co Ltd to the Biotechnology industry mean.
  • 3.0% Return on Equity means Samsung Biologics Co Ltd generated ₩0.03 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Samsung Biologics Co Ltd:

  • The MRQ is 3.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.0%TTM2.3%+0.7%
TTM2.3%YOY2.7%-0.4%
TTM2.3%5Y1.9%+0.4%
5Y1.9%10Y1.6%+0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0%-16.9%+19.9%
TTM2.3%-16.1%+18.4%
YOY2.7%-14.9%+17.6%
5Y1.9%-19.3%+21.2%
10Y1.6%-20.1%+21.7%

1.2. Operating Efficiency of Samsung Biologics Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Samsung Biologics Co Ltd is operating .

  • Measures how much profit Samsung Biologics Co Ltd makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Samsung Biologics Co Ltd to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Samsung Biologics Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM7.3%-7.3%
TTM7.3%YOY32.5%-25.2%
TTM7.3%5Y27.4%-20.1%
5Y27.4%10Y24.5%+2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM7.3%-238.5%+245.8%
YOY32.5%-288.4%+320.9%
5Y27.4%-486.2%+513.6%
10Y24.5%-628.4%+652.9%
1.2.2. Operating Ratio

Measures how efficient Samsung Biologics Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.18 means that the operating costs are ₩1.18 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Samsung Biologics Co Ltd:

  • The MRQ is 1.179. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.165. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.179TTM1.165+0.015
TTM1.165YOY1.074+0.090
TTM1.1655Y1.303-0.138
5Y1.30310Y1.360-0.058
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1793.235-2.056
TTM1.1653.310-2.145
YOY1.0743.838-2.764
5Y1.3035.679-4.376
10Y1.3607.823-6.463

1.3. Liquidity of Samsung Biologics Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Samsung Biologics Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.33 means the company has ₩1.33 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Samsung Biologics Co Ltd:

  • The MRQ is 1.328. The company is just able to pay all its short-term debts.
  • The TTM is 1.419. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.328TTM1.419-0.091
TTM1.419YOY1.671-0.251
TTM1.4195Y2.107-0.688
5Y2.10710Y1.876+0.232
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3283.863-2.535
TTM1.4194.169-2.750
YOY1.6715.337-3.666
5Y2.1076.122-4.015
10Y1.8766.434-4.558
1.3.2. Quick Ratio

Measures if Samsung Biologics Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Samsung Biologics Co Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 0.41 means the company can pay off ₩0.41 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Samsung Biologics Co Ltd:

  • The MRQ is 0.406. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.381. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.406TTM0.381+0.025
TTM0.381YOY0.726-0.345
TTM0.3815Y0.963-0.582
5Y0.96310Y0.881+0.082
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4063.504-3.098
TTM0.3813.991-3.610
YOY0.7265.371-4.645
5Y0.9636.088-5.125
10Y0.8816.395-5.514

1.4. Solvency of Samsung Biologics Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Samsung Biologics Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Samsung Biologics Co Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.39 means that Samsung Biologics Co Ltd assets are financed with 38.7% credit (debt) and the remaining percentage (100% - 38.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Samsung Biologics Co Ltd:

  • The MRQ is 0.387. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.409. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.387TTM0.409-0.022
TTM0.409YOY0.460-0.051
TTM0.4095Y0.349+0.060
5Y0.34910Y0.363-0.014
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3870.339+0.048
TTM0.4090.337+0.072
YOY0.4600.271+0.189
5Y0.3490.368-0.019
10Y0.3630.388-0.025
1.4.2. Debt to Equity Ratio

Measures if Samsung Biologics Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Samsung Biologics Co Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 63.2% means that company has ₩0.63 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Samsung Biologics Co Ltd:

  • The MRQ is 0.632. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.694. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.632TTM0.694-0.062
TTM0.694YOY0.853-0.158
TTM0.6945Y0.559+0.135
5Y0.55910Y0.595-0.036
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6320.392+0.240
TTM0.6940.403+0.291
YOY0.8530.335+0.518
5Y0.5590.427+0.132
10Y0.5950.461+0.134

2. Market Valuation of Samsung Biologics Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Samsung Biologics Co Ltd generates.

  • Above 15 is considered overpriced but always compare Samsung Biologics Co Ltd to the Biotechnology industry mean.
  • A PE ratio of 46.52 means the investor is paying ₩46.52 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Samsung Biologics Co Ltd:

  • The EOD is 47.746. Based on the earnings, the company is overpriced. -1
  • The MRQ is 46.522. Based on the earnings, the company is overpriced. -1
  • The TTM is 66.862. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD47.746MRQ46.522+1.224
MRQ46.522TTM66.862-20.341
TTM66.862YOY85.815-18.953
TTM66.8625Y86.579-19.717
5Y86.57910Y2.902+83.677
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD47.746-2.300+50.046
MRQ46.522-2.656+49.178
TTM66.862-2.718+69.580
YOY85.815-4.145+89.960
5Y86.579-6.258+92.837
10Y2.902-6.315+9.217
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Samsung Biologics Co Ltd:

  • The EOD is 25.998. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 25.331. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 66.663. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD25.998MRQ25.331+0.667
MRQ25.331TTM66.663-41.331
TTM66.663YOY19.777+46.886
TTM66.6635Y789.974-723.312
5Y789.97410Y520.636+269.339
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD25.998-2.974+28.972
MRQ25.331-3.306+28.637
TTM66.663-3.508+70.171
YOY19.777-5.613+25.390
5Y789.974-8.378+798.352
10Y520.636-8.873+529.509
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Samsung Biologics Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.50 means the investor is paying ₩5.50 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Samsung Biologics Co Ltd:

  • The EOD is 5.647. Based on the equity, the company is overpriced. -1
  • The MRQ is 5.502. Based on the equity, the company is overpriced. -1
  • The TTM is 5.603. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD5.647MRQ5.502+0.145
MRQ5.502TTM5.603-0.101
TTM5.603YOY8.356-2.753
TTM5.6035Y8.634-3.031
5Y8.63410Y8.390+0.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.6471.914+3.733
MRQ5.5022.116+3.386
TTM5.6032.097+3.506
YOY8.3562.881+5.475
5Y8.6343.550+5.084
10Y8.3903.936+4.454
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Samsung Biologics Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--3996.8552971.654+34%14026.794-72%3986.725+0%5312.275-25%
Book Value Per Share--138119.150132822.200+4%106769.190+29%85852.668+61%78918.242+75%
Current Ratio--1.3281.419-6%1.671-21%2.107-37%1.876-29%
Debt To Asset Ratio--0.3870.409-5%0.460-16%0.349+11%0.363+7%
Debt To Equity Ratio--0.6320.694-9%0.853-26%0.559+13%0.595+6%
Dividend Per Share----0%-0%-0%-0%
Eps--4084.1253012.657+36%2803.187+46%1751.493+133%1445.820+182%
Free Cash Flow Per Share--7500.5431970.185+281%-197.326+103%295.509+2438%-9.005+100%
Free Cash Flow To Equity Per Share--7500.5431377.492+445%10340.512-27%2688.044+179%2049.650+266%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--351857.946--------
Intrinsic Value_10Y_min--292938.033--------
Intrinsic Value_1Y_max--7269.486--------
Intrinsic Value_1Y_min--7123.945--------
Intrinsic Value_3Y_max--43172.846--------
Intrinsic Value_3Y_min--40785.737--------
Intrinsic Value_5Y_max--104793.253--------
Intrinsic Value_5Y_min--95430.468--------
Market Cap55515720000000.000+3%54092240000000.00052900075500000.000+2%57739907500000.000-6%48885867165452.523+11%44538504645194.406+21%
Net Profit Margin--0.2710.228+19%0.263+3%0.210+29%0.210+29%
Operating Margin---0.073-100%0.325-100%0.274-100%0.245-100%
Operating Ratio--1.1791.165+1%1.074+10%1.303-9%1.360-13%
Pb Ratio5.647+3%5.5025.603-2%8.356-34%8.634-36%8.390-34%
Pe Ratio47.746+3%46.52266.862-30%85.815-46%86.579-46%2.902+1503%
Price Per Share780000.000+3%760000.000743250.000+2%811250.000-6%686850.074+11%625769.307+21%
Price To Free Cash Flow Ratio25.998+3%25.33166.663-62%19.777+28%789.974-97%520.636-95%
Price To Total Gains Ratio195.153+3%190.150269.595-29%130.319+46%303.744-37%14.476+1214%
Quick Ratio--0.4060.381+7%0.726-44%0.963-58%0.881-54%
Return On Assets--0.0180.013+35%0.015+24%0.012+51%0.011+72%
Return On Equity--0.0300.023+31%0.027+9%0.019+56%0.016+83%
Total Gains Per Share--3996.8552971.654+34%14026.794-72%3986.725+0%5312.275-25%
Usd Book Value--6881344688.6386617441093.393+4%5319433224.378+29%4277334433.192+61%3931848871.498+75%
Usd Book Value Change Per Share--2.7982.080+34%9.819-72%2.791+0%3.719-25%
Usd Book Value Per Share--96.68392.976+4%74.738+29%60.097+61%55.243+75%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--2.8592.109+36%1.962+46%1.226+133%1.012+182%
Usd Free Cash Flow--373690560.04798158175.225+281%-9831115.161+103%14722814.583+2438%-448629.645+100%
Usd Free Cash Flow Per Share--5.2501.379+281%-0.138+103%0.207+2438%-0.006+100%
Usd Free Cash Flow To Equity Per Share--5.2500.964+445%7.238-27%1.882+179%1.435+266%
Usd Market Cap38861004000.000+3%37864568000.00037030052850.000+2%40417935250.000-6%34220107015.817+11%31176953251.636+21%
Usd Price Per Share546.000+3%532.000520.275+2%567.875-6%480.795+11%438.039+21%
Usd Profit--203478476.418150095977.201+36%139659836.885+46%87262555.668+133%72033363.422+182%
Usd Revenue--751456110.447646553034.311+16%525226659.655+43%354559086.962+112%295072329.180+155%
Usd Total Gains Per Share--2.7982.080+34%9.819-72%2.791+0%3.719-25%
 EOD+4 -4MRQTTM+28 -5YOY+19 -145Y+26 -710Y+22 -11

3.2. Fundamental Score

Let's check the fundamental score of Samsung Biologics Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1547.746
Price to Book Ratio (EOD)Between0-15.647
Net Profit Margin (MRQ)Greater than00.271
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.406
Current Ratio (MRQ)Greater than11.328
Debt to Asset Ratio (MRQ)Less than10.387
Debt to Equity Ratio (MRQ)Less than10.632
Return on Equity (MRQ)Greater than0.150.030
Return on Assets (MRQ)Greater than0.050.018
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Samsung Biologics Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.082
Ma 20Greater thanMa 50801,550.000
Ma 50Greater thanMa 100813,760.000
Ma 100Greater thanMa 200785,900.000
OpenGreater thanClose783,000.000
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Long-term Assets Other  -9,317,940-1,558,943-10,876,883-392,133-11,269,01611,269,016011



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets16,046,197,209
Total Liabilities6,215,704,797
Total Stockholder Equity9,830,492,412
 As reported
Total Liabilities 6,215,704,797
Total Stockholder Equity+ 9,830,492,412
Total Assets = 16,046,197,209

Assets

Total Assets16,046,197,209
Total Current Assets5,521,987,757
Long-term Assets10,524,209,453
Total Current Assets
Cash And Cash Equivalents 367,937,365
Short-term Investments 1,688,338,324
Inventory 2,641,368,466
Other Current Assets 1
Total Current Assets  (as reported)5,521,987,757
Total Current Assets  (calculated)4,697,644,156
+/- 824,343,600
Long-term Assets
Property Plant Equipment 4,342,423,619
Goodwill 1,677,607,967
Intangible Assets 4,154,480,190
Long-term Assets Other 1
Long-term Assets  (as reported)10,524,209,453
Long-term Assets  (calculated)10,174,511,777
+/- 349,697,676

Liabilities & Shareholders' Equity

Total Current Liabilities4,157,860,817
Long-term Liabilities2,057,843,979
Total Stockholder Equity9,830,492,412
Total Current Liabilities
Short Long Term Debt 1,387,905,014
Accounts payable 208,277,666
Other Current Liabilities 863,719
Total Current Liabilities  (as reported)4,157,860,817
Total Current Liabilities  (calculated)1,597,046,399
+/- 2,560,814,419
Long-term Liabilities
Long term Debt 239,782,550
Capital Lease Obligations Min Short Term Debt281,645,013
Long-term Liabilities Other 200,067
Long-term Liabilities  (as reported)2,057,843,979
Long-term Liabilities  (calculated)521,627,631
+/- 1,536,216,349
Total Stockholder Equity
Retained Earnings 4,003,292,734
Total Stockholder Equity (as reported)9,830,492,412
Total Stockholder Equity (calculated)4,003,292,734
+/- 5,827,199,678
Other
Capital Stock177,935,000
Common Stock Shares Outstanding 71,174
Net Debt 1,259,750,199
Net Invested Capital 11,458,179,976
Net Working Capital 1,364,126,939
Property Plant and Equipment Gross 5,399,777,187



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
> Total Assets 
7,108,299,280
7,183,091,163
7,129,746,766
7,341,191,746
5,980,408,648
5,980,408,648
5,887,963,181
5,826,642,800
5,785,057,220
5,911,626,512
5,944,971,454
6,032,874,721
6,137,199,100
6,424,201,165
6,479,106,813
6,611,019,819
7,594,303,612
7,970,010,787
7,998,208,574
15,659,441,913
16,091,757,036
16,582,050,258
16,381,707,091
15,701,801,078
15,887,670,237
16,046,197,209
16,046,197,20915,887,670,23715,701,801,07816,381,707,09116,582,050,25816,091,757,03615,659,441,9137,998,208,5747,970,010,7877,594,303,6126,611,019,8196,479,106,8136,424,201,1656,137,199,1006,032,874,7215,944,971,4545,911,626,5125,785,057,2205,826,642,8005,887,963,1815,980,408,6485,980,408,6487,341,191,7467,129,746,7667,183,091,1637,108,299,280
   > Total Current Assets 
616,779,477
620,995,135
671,552,724
3,085,272,525
1,577,683,716
1,577,683,716
1,480,260,089
1,387,127,969
1,338,602,059
1,356,261,664
1,428,490,588
1,516,689,246
1,569,087,980
1,751,347,248
1,790,017,816
1,780,215,625
2,608,317,878
2,823,175,325
2,661,259,307
6,344,591,744
6,322,562,630
6,457,656,567
6,114,176,466
5,222,084,238
5,426,432,659
5,521,987,757
5,521,987,7575,426,432,6595,222,084,2386,114,176,4666,457,656,5676,322,562,6306,344,591,7442,661,259,3072,823,175,3252,608,317,8781,780,215,6251,790,017,8161,751,347,2481,569,087,9801,516,689,2461,428,490,5881,356,261,6641,338,602,0591,387,127,9691,480,260,0891,577,683,7161,577,683,7163,085,272,525671,552,724620,995,135616,779,477
       Cash And Cash Equivalents 
316,038,255
358,088,091
337,928,764
87,894,471
17,621,905
17,621,905
49,246,401
10,603,570
20,500,723
125,100,653
40,766,901
68,961,750
57,022,224
28,850,121
60,442,973
81,454,198
137,553,354
47,410,384
381,869,943
213,005,106
375,432,993
890,819,571
1,522,192,963
534,817,741
279,185,318
367,937,365
367,937,365279,185,318534,817,7411,522,192,963890,819,571375,432,993213,005,106381,869,94347,410,384137,553,35481,454,19860,442,97328,850,12157,022,22468,961,75040,766,901125,100,65320,500,72310,603,57049,246,40117,621,90517,621,90587,894,471337,928,764358,088,091316,038,255
       Short-term Investments 
0
0
0
0
1,110,960,126
1,110,960,126
1,001,112,839
857,265,717
688,271,592
564,822,304
708,158,772
725,130,668
847,486,447
823,602,031
586,577,731
438,996,362
1,133,224,375
1,324,024,822
906,596,271
2,970,557,098
2,760,233,634
2,302,717,696
1,442,866,076
1,333,098,657
1,538,207,041
1,688,338,324
1,688,338,3241,538,207,0411,333,098,6571,442,866,0762,302,717,6962,760,233,6342,970,557,098906,596,2711,324,024,8221,133,224,375438,996,362586,577,731823,602,031847,486,447725,130,668708,158,772564,822,304688,271,592857,265,7171,001,112,8391,110,960,1261,110,960,1260000
       Net Receivables 
74,831,082
25,817,150
66,283,235
88,914,143
141,232,526
141,232,526
71,883,279
63,215,643
142,902,877
181,123,111
140,636,717
205,174,260
400,000
400,000
400,000
400,000
0
0
0
684,002,282
0
0
0
0
0
0
000000684,002,282000400,000400,000400,000400,000205,174,260140,636,717181,123,111142,902,87763,215,64371,883,279141,232,526141,232,52688,914,14366,283,23525,817,15074,831,082
       Inventory 
194,628,723
209,986,717
223,534,583
231,581,065
302,360,715
302,360,715
320,550,335
415,476,462
445,669,454
452,469,927
505,885,416
495,672,529
555,769,918
645,960,096
788,273,744
879,623,748
959,642,055
1,012,870,791
1,012,841,766
2,306,426,858
2,389,422,600
2,375,818,961
2,437,974,764
2,529,884,577
2,551,229,441
2,641,368,466
2,641,368,4662,551,229,4412,529,884,5772,437,974,7642,375,818,9612,389,422,6002,306,426,8581,012,841,7661,012,870,791959,642,055879,623,748788,273,744645,960,096555,769,918495,672,529505,885,416452,469,927445,669,454415,476,462320,550,335302,360,715302,360,715231,581,065223,534,583209,986,717194,628,723
       Other Current Assets 
25,968,081
22,762,327
37,555,057
2,283,086,964
5,508,443
5,508,443
-1
0
0
0
22,996,253
16,448,950
100,065,672
245,810,624
342,034,812
373,199,235
367,216,247
430,290,615
345,309,822
154,820,064
775,033,185
865,098,907
0
804,724,687
0
1
10804,724,6870865,098,907775,033,185154,820,064345,309,822430,290,615367,216,247373,199,235342,034,812245,810,624100,065,67216,448,95022,996,253000-15,508,4435,508,4432,283,086,96437,555,05722,762,32725,968,081
   > Long-term Assets 
0
0
0
0
0
0
4,407,703,093
4,439,514,831
4,446,455,160
4,555,364,848
4,516,480,866
4,516,185,476
4,568,111,120
4,672,853,917
4,689,088,997
4,830,804,194
4,985,985,734
5,146,835,462
5,336,949,267
9,314,850,168
9,769,194,407
10,124,393,691
10,267,530,626
10,479,716,840
10,461,237,578
10,524,209,453
10,524,209,45310,461,237,57810,479,716,84010,267,530,62610,124,393,6919,769,194,4079,314,850,1685,336,949,2675,146,835,4624,985,985,7344,830,804,1944,689,088,9974,672,853,9174,568,111,1204,516,185,4764,516,480,8664,555,364,8484,446,455,1604,439,514,8314,407,703,093000000
       Property Plant Equipment 
1,414,614,934
1,513,332,618
1,584,529,534
1,624,361,234
1,717,720,988
1,717,720,988
0
0
0
0
1,697,331,118
1,692,202,826
1,689,066,928
1,760,727,513
1,815,987,750
1,934,042,427
2,055,402,202
2,227,687,479
2,392,027,144
2,887,130,045
3,541,255,914
3,871,452,333
4,033,173,084
4,280,510,390
4,272,916,014
4,342,423,619
4,342,423,6194,272,916,0144,280,510,3904,033,173,0843,871,452,3333,541,255,9142,887,130,0452,392,027,1442,227,687,4792,055,402,2021,934,042,4271,815,987,7501,760,727,5131,689,066,9281,692,202,8261,697,331,11800001,717,720,9881,717,720,9881,624,361,2341,584,529,5341,513,332,6181,414,614,934
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,588,320,417
1,697,278,497
1,677,607,967
1,677,607,967
1,677,607,967
1,677,607,967
1,677,607,967
1,677,607,9671,677,607,9671,677,607,9671,677,607,9671,677,607,9671,697,278,4971,588,320,4170000000000000000000
       Long Term Investments 
5,043,366,050
5,008,234,005
4,803,346,584
2,527,811,143
2,586,032,876
2,586,032,876
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000002,586,032,8762,586,032,8762,527,811,1434,803,346,5845,008,234,0055,043,366,050
       Intangible Assets 
16,132,530
18,999,003
18,931,894
18,590,491
19,981,634
19,981,634
21,450,433
22,638,251
22,530,012
21,827,515
20,872,395
22,971,589
24,342,695
23,344,606
25,075,481
31,759,315
31,889,244
32,171,618
31,139,307
4,401,091,864
4,244,504,881
4,283,698,718
4,255,501,898
4,230,581,544
4,179,914,987
4,154,480,190
4,154,480,1904,179,914,9874,230,581,5444,255,501,8984,283,698,7184,244,504,8814,401,091,86431,139,30732,171,61831,889,24431,759,31525,075,48123,344,60624,342,69522,971,58920,872,39521,827,51522,530,01222,638,25121,450,43319,981,63419,981,63418,590,49118,931,89418,999,00316,132,530
       Long-term Assets Other 
0
0
0
0
0
0
9,603,635
7,755,346
4,985,560
-2,005,980
-4,280,588
-3,147,329
-2,099,922
0
-1,154,884
-1,929,828
-6,798,762
-8,183,942
-14,111,636
-27,504,972
-45,808,724
-9,317,940
-10,876,883
-11,269,016
0
1
10-11,269,016-10,876,883-9,317,940-45,808,724-27,504,972-14,111,636-8,183,942-6,798,762-1,929,828-1,154,8840-2,099,922-3,147,329-4,280,588-2,005,9804,985,5607,755,3469,603,635000000
> Total Liabilities 
3,117,136,850
3,206,640,270
3,349,891,471
3,569,051,559
1,824,940,197
1,824,940,197
1,771,505,594
1,723,512,737
1,637,687,025
1,557,172,767
1,553,373,834
1,589,676,045
1,638,363,580
1,825,417,993
1,819,246,011
1,829,988,176
2,681,279,928
2,978,908,646
3,676,402,358
7,179,559,648
7,481,158,630
7,597,575,863
7,255,295,052
6,390,776,713
6,341,649,949
6,215,704,797
6,215,704,7976,341,649,9496,390,776,7137,255,295,0527,597,575,8637,481,158,6307,179,559,6483,676,402,3582,978,908,6462,681,279,9281,829,988,1761,819,246,0111,825,417,9931,638,363,5801,589,676,0451,553,373,8341,557,172,7671,637,687,0251,723,512,7371,771,505,5941,824,940,1971,824,940,1973,569,051,5593,349,891,4713,206,640,2703,117,136,850
   > Total Current Liabilities 
2,175,061,836
2,287,442,106
2,342,789,915
2,304,119,041
710,529,787
710,529,787
659,704,973
618,724,234
716,316,324
690,505,243
674,182,950
833,483,684
625,855,215
589,300,919
557,434,308
532,713,980
886,479,304
1,107,294,649
1,748,077,300
3,467,675,543
3,538,555,974
4,181,541,561
3,884,888,712
3,590,807,584
4,107,625,985
4,157,860,817
4,157,860,8174,107,625,9853,590,807,5843,884,888,7124,181,541,5613,538,555,9743,467,675,5431,748,077,3001,107,294,649886,479,304532,713,980557,434,308589,300,919625,855,215833,483,684674,182,950690,505,243716,316,324618,724,234659,704,973710,529,787710,529,7872,304,119,0412,342,789,9152,287,442,1062,175,061,836
       Short-term Debt 
76,250,000
98,676,578
146,195,458
130,179,628
386,583,355
386,583,355
387,146,446
360,400,000
464,150,000
401,650,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000401,650,000464,150,000360,400,000387,146,446386,583,355386,583,355130,179,628146,195,45898,676,57876,250,000
       Short Long Term Debt 
76,250,000
98,676,578
146,195,458
130,179,628
386,583,355
386,583,355
387,146,446
360,400,000
464,150,000
401,650,000
366,376,000
498,450,775
286,847,455
190,907,459
149,960,295
0
129,849,000
159,855,000
160,108,000
997,340,068
725,355,454
1,138,800,019
1,138,207,880
1,142,884,000
1,565,100,049
1,387,905,014
1,387,905,0141,565,100,0491,142,884,0001,138,207,8801,138,800,019725,355,454997,340,068160,108,000159,855,000129,849,0000149,960,295190,907,459286,847,455498,450,775366,376,000401,650,000464,150,000360,400,000387,146,446386,583,355386,583,355130,179,628146,195,45898,676,57876,250,000
       Accounts payable 
323,384
14,479,382
20,334,298
13,494,923
170,338,294
170,338,294
15,146,234
15,261,933
13,669,914
12,289,708
18,433,475
27,004,892
37,486,347
54,984,011
40,876,893
61,655,077
61,777,087
32,250,587
43,358,651
97,820,270
95,772,900
59,616,055
0
167,477,593
164,491,813
208,277,666
208,277,666164,491,813167,477,593059,616,05595,772,90097,820,27043,358,65132,250,58761,777,08761,655,07740,876,89354,984,01137,486,34727,004,89218,433,47512,289,70813,669,91415,261,93315,146,234170,338,294170,338,29413,494,92320,334,29814,479,382323,384
       Other Current Liabilities 
1,979,129,323
2,039,400,573
2,084,842,072
2,072,772,527
153,608,138
153,608,138
1,868,066
405,364
467,849
553,853
258,534,061
261,366,069
250,476,965
272,520,536
321,182,282
403,218,160
524,875,924
833,330,405
1,437,802,045
2,150,466,901
2,409,635,758
2,633,441,101
717,751
1,889,921,513
926,439
863,719
863,719926,4391,889,921,513717,7512,633,441,1012,409,635,7582,150,466,9011,437,802,045833,330,405524,875,924403,218,160321,182,282272,520,536250,476,965261,366,069258,534,061553,853467,849405,3641,868,066153,608,138153,608,1382,072,772,5272,084,842,0722,039,400,5731,979,129,323
   > Long-term Liabilities 
0
0
0
0
0
0
1,111,800,621
1,104,788,504
921,370,702
866,667,524
879,190,885
756,192,361
1,012,508,364
1,236,117,073
1,261,811,703
1,297,274,196
1,794,800,624
1,871,613,997
1,928,325,058
3,711,884,106
3,942,602,657
3,416,034,302
3,370,406,340
2,799,969,130
2,234,023,963
2,057,843,979
2,057,843,9792,234,023,9632,799,969,1303,370,406,3403,416,034,3023,942,602,6573,711,884,1061,928,325,0581,871,613,9971,794,800,6241,297,274,1961,261,811,7031,236,117,0731,012,508,364756,192,361879,190,885866,667,524921,370,7021,104,788,5041,111,800,621000000
       Capital Lease Obligations 
0
0
0
0
0
0
9,128,901
8,365,902
8,126,823
15,889,284
15,664,221
16,684,906
18,293,319
22,546,905
25,440,577
24,267,476
23,648,979
18,208,298
16,717,850
16,726,841
401,785,846
410,142,588
347,796,220
352,236,650
281,075,042
281,645,013
281,645,013281,075,042352,236,650347,796,220410,142,588401,785,84616,726,84116,717,85018,208,29823,648,97924,267,47625,440,57722,546,90518,293,31916,684,90615,664,22115,889,2848,126,8238,365,9029,128,901000000
       Long-term Liabilities Other 
0
0
0
0
0
0
1
0
1
0
0
0
0
-1
1
0
0
0
0
41,541
0
0
119,787
119,540
199,385
200,067
200,067199,385119,540119,7870041,54100001-10000101000000
       Deferred Long Term Liability 
0
0
30,352,499
59,531,235
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,362,439,782
4,202,340,985
2,741,848,255
0
2,703,339,804
0
0
002,703,339,80402,741,848,2554,202,340,9854,362,439,78200000000000000059,531,23530,352,49900
> Total Stockholder Equity
3,991,162,430
3,976,450,893
3,779,855,295
3,772,140,187
4,155,468,451
4,155,468,451
4,116,457,588
4,103,130,062
4,147,370,194
4,354,453,745
4,391,597,619
4,443,198,676
4,498,835,520
4,598,783,172
4,659,860,802
4,781,031,643
4,913,023,685
4,991,102,141
4,321,806,215
8,479,882,264
8,610,598,406
8,984,474,395
9,126,412,040
9,311,024,364
9,546,020,288
9,830,492,412
9,830,492,4129,546,020,2889,311,024,3649,126,412,0408,984,474,3958,610,598,4068,479,882,2644,321,806,2154,991,102,1414,913,023,6854,781,031,6434,659,860,8024,598,783,1724,498,835,5204,443,198,6764,391,597,6194,354,453,7454,147,370,1944,103,130,0624,116,457,5884,155,468,4514,155,468,4513,772,140,1873,779,855,2953,976,450,8933,991,162,430
   Common Stock
165,412,500
165,412,500
165,412,500
165,412,500
165,412,500
165,412,500
0
165,400,000
0
0
165,412,500
165,412,500
165,412,500
165,412,500
165,412,500
165,412,500
165,412,500
165,412,500
165,412,500
177,935,000
177,935,000
177,935,000
0
177,935,000
0
0
00177,935,0000177,935,000177,935,000177,935,000165,412,500165,412,500165,412,500165,412,500165,412,500165,412,500165,412,500165,412,500165,412,50000165,400,0000165,412,500165,412,500165,412,500165,412,500165,412,500165,412,500
   Retained Earnings 
1,337,835,734
1,327,734,757
1,131,311,401
1,121,728,719
1,509,718,830
1,509,718,830
1,471,268,750
1,457,857,478
1,502,001,003
1,712,622,929
1,749,275,955
1,801,294,632
1,857,376,003
1,953,597,729
2,014,573,266
2,136,095,724
2,267,869,259
2,347,187,197
2,494,129,929
2,646,528,227
2,775,692,257
3,145,601,436
3,287,356,809
3,472,242,484
3,712,609,196
4,003,292,734
4,003,292,7343,712,609,1963,472,242,4843,287,356,8093,145,601,4362,775,692,2572,646,528,2272,494,129,9292,347,187,1972,267,869,2592,136,095,7242,014,573,2661,953,597,7291,857,376,0031,801,294,6321,749,275,9551,712,622,9291,502,001,0031,457,857,4781,471,268,7501,509,718,8301,509,718,8301,121,728,7191,131,311,4011,327,734,7571,337,835,734
   Capital Surplus 00000000000000000000000000
   Treasury Stock00000000000000000000000000
   Other Stockholders Equity 
601,114
-4,009,446
-4,181,688
-2,314,114
-6,975,961
-6,975,961
0
-7,500,000
0
0
-10,403,918
-10,821,538
-11,266,065
-7,540,139
-7,438,046
-7,789,663
-7,571,156
-8,810,638
-9,187,952
-7,692,315
-6,140,204
-2,173,393
0
-2,264,473
0
0
00-2,264,4730-2,173,393-6,140,204-7,692,315-9,187,952-8,810,638-7,571,156-7,789,663-7,438,046-7,540,139-11,266,065-10,821,538-10,403,91800-7,500,0000-6,975,961-6,975,961-2,314,114-4,181,688-4,009,446601,114



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue3,694,588,767
Cost of Revenue-1,891,824,206
Gross Profit1,802,764,5611,802,764,561
 
Operating Income (+$)
Gross Profit1,802,764,561
Operating Expense-2,580,908,758
Operating Income1,113,680,009-778,144,196
 
Operating Expense (+$)
Research Development81,587,988
Selling General Administrative303,534,451
Selling And Marketing Expenses0
Operating Expense2,580,908,758385,122,439
 
Net Interest Income (+$)
Interest Income95,650,057
Interest Expense-81,596,401
Other Finance Cost-1
Net Interest Income14,053,655
 
Pretax Income (+$)
Operating Income1,113,680,009
Net Interest Income14,053,655
Other Non-Operating Income Expenses0
Income Before Tax (EBT)1,119,986,9311,113,680,009
EBIT - interestExpense = -81,596,401
857,691,298
939,287,699
Interest Expense81,596,401
Earnings Before Interest and Taxes (EBIT)01,201,583,332
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax1,119,986,931
Tax Provision-262,295,633
Net Income From Continuing Ops857,691,298857,691,298
Net Income857,691,298
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-14,053,655
 

Technical Analysis of Samsung Biologics Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Samsung Biologics Co Ltd. The general trend of Samsung Biologics Co Ltd is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Samsung Biologics Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Samsung Biologics Co Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 874,000 < 874,000 < 878,000.

The bearish price targets are: 768,000 > 745,000 > 743,000.

Tweet this
Samsung Biologics Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Samsung Biologics Co Ltd. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Samsung Biologics Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Samsung Biologics Co Ltd. The current macd is -9,511.3713508.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Samsung Biologics Co Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Samsung Biologics Co Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Samsung Biologics Co Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Samsung Biologics Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartSamsung Biologics Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Samsung Biologics Co Ltd. The current adx is 20.05.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Samsung Biologics Co Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Samsung Biologics Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Samsung Biologics Co Ltd. The current sar is 771,386.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Samsung Biologics Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Samsung Biologics Co Ltd. The current rsi is 40.08. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Samsung Biologics Co Ltd Daily Relative Strength Index (RSI) ChartSamsung Biologics Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Samsung Biologics Co Ltd. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Samsung Biologics Co Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Samsung Biologics Co Ltd Daily Stochastic Oscillator ChartSamsung Biologics Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Samsung Biologics Co Ltd. The current cci is -93.50764458.

Samsung Biologics Co Ltd Daily Commodity Channel Index (CCI) ChartSamsung Biologics Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Samsung Biologics Co Ltd. The current cmo is -24.38750171.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Samsung Biologics Co Ltd Daily Chande Momentum Oscillator (CMO) ChartSamsung Biologics Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Samsung Biologics Co Ltd. The current willr is -80.39215686.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Samsung Biologics Co Ltd Daily Williams %R ChartSamsung Biologics Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Samsung Biologics Co Ltd.

Samsung Biologics Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Samsung Biologics Co Ltd. The current atr is 17,639.

Samsung Biologics Co Ltd Daily Average True Range (ATR) ChartSamsung Biologics Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Samsung Biologics Co Ltd. The current obv is -437,440.

Samsung Biologics Co Ltd Daily On-Balance Volume (OBV) ChartSamsung Biologics Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Samsung Biologics Co Ltd. The current mfi is 28.68.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Samsung Biologics Co Ltd Daily Money Flow Index (MFI) ChartSamsung Biologics Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Samsung Biologics Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Samsung Biologics Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Samsung Biologics Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.082
Ma 20Greater thanMa 50801,550.000
Ma 50Greater thanMa 100813,760.000
Ma 100Greater thanMa 200785,900.000
OpenGreater thanClose783,000.000
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Samsung Biologics Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Samsung Biologics Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Samsung Biologics Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Samsung Biologics Co Ltd

I send you an email if I find something interesting about Samsung Biologics Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Samsung Biologics Co Ltd.

Receive notifications about Samsung Biologics Co Ltd in your mailbox!